Navigation Links
EnteroMedics to Participate in Canaccord Genuity 34th Annual Growth Conference
Date:8/6/2014

ST. PAUL, Minn., Aug. 6, 2014 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, PhD., EnteroMedics' President and Chief Executive Officer is scheduled to participate in the Canaccord Genuity 34th Annual Growth Conference.  The event will be held on August 14, 2014 at 11:30 am Eastern Time at the InterContinental Hotel, Boston, MA.

Dr. Knudson will provide an overview of EnteroMedics and its development and commercialization program for VBLOC® vagal blocking therapy.

The presentation will be webcast live and may be accessed by visiting EnteroMedics' website at www.enteromedics.com. A replay of the webcast will also be available immediately after the conclusion of the presentation for a period of ninety days. Investors can access the webcast under "Events" in the "Investors" section of EnteroMedics' website.

Institutional investors who wish to request a meeting with EnteroMedics should contact Canaccord Genuity.

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. VBLOC® vagal blocking therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses, which helps control both hunger and fullness. VBLOC allows people with obesity to take a positive path towards weight loss, addressing the lifelong challenge of obesity and its comorbidities without sacrificing wellbeing or comfort.  EnteroMedics' Maestro Rechargeable System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial regulatory approval for our Maestro® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our preliminary findings from our EMPOWER™ and ReCharge pivotal trials; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and VBLOC® vagal blocking therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 27, 2014. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Caution - Investigational device. Limited by Federal (United States) law to investigational use.

The implantation procedure and usage of the Maestro® System carry some risks, such as the risks generally associated with laparoscopic procedures and those related to treatment as described in the ReCharge clinical study informed consent.


'/>"/>
SOURCE EnteroMedics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call
2. WAISMANN METHOD® Director Encourages Public to Participate in National Take-Back Day
3. Hill-Rom to Participate in the Deutsche Bank Securities Health Care Conference
4. Hill-Rom to Participate in the Bank of America Merrill Lynch 2012 Health Care Conference
5. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
6. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
7. BlackStratus participates in Joint FDA-ISPE CGMP Conference
8. ViroPharma To Participate In The JMP Securities Healthcare Conference
9. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
10. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
11. Misonix Participates In Cleveland Spine Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 18, 2017 , , Marks E-QURE ... rd distribution agreement, following similar agreements in ... Wound care is $2 5 ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the ... Tech - Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia ...
(Date:1/19/2017)... Jan. 18, 2017  Magnetic Insight Inc., leader ... into an agreement with inviCRO LLC to develop ... imaging system based on inviCRO,s VivoQuant™ visualization and ... as a complete MPI solution package with the ... or cell imaging in vivo. MPI ...
(Date:1/19/2017)... 2017 The Academy of Managed Care ... (FDA) for its release today of draft guidance ... makers can proactively share clinical and economic information ... emerging therapies awaiting FDA approval. ... AMCP developed during two multi-stakeholder meetings last year ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate Medical Academy ... who are passionate about making a difference in the lives of the next ... UMA, a nonprofit healthcare educational institution, has more than 30,000 alumni and employs ...
(Date:1/19/2017)... Ashland, VA (PRWEB) , ... January 19, 2017 , ... ... planning services to the eastern Virginia region, is inaugurating a charity event to honor ... community. , While on duty last year, Chad Phillip Dermyer and his fellow officers ...
(Date:1/19/2017)... ... 19, 2017 , ... Creative messages to prevent distracted driving ... Impact Teen Drivers and California Casualty. Entries from students aged 14-22 can be ... $15,000 will be awarded for the best peer-to-peer messages sharing solutions to reckless ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) is proud and ... and compassionate dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care ... considerable pleasure to welcome back Dr. Kim to the CDG team” said President and ...
(Date:1/19/2017)... ... , ... Infinity® Massage Chairs announced today that Dan Grover has joined the ... Grover comes with a total of 15 years experience in consumer goods and an ... President of Direct Sales at Traeger® Wood Pellet Grills. , Grover has elevated ...
Breaking Medicine News(10 mins):